• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 451533 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419089950 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419089950 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Bristol-Myers Squibb Rise to a New 52-Week High

Published on Fri, 03/01/2013 - 15:10
By Peter Chu

Bristol-Myers Squibb (NYSE:BMY) traded today at a new 52-week high of $37.25. So far today approximately 5.9 million shares have been exchanged, as compared to an average 30-day volume of 9.5 million shares.

In the past 52 weeks, Bristol-Myers Squibb share prices have been bracketed by a low of $30.64 and a high of $37.25 and are now at $37.08, 21% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.9%.

Bristol-Myers Squibb (NYSE:BMY) is currently priced 3.2% above its average consensus analyst price target of $35.91. The stock should find initial support at its 50-day moving average (MA) of $34.99 and further support at its 200-day MA of $33.86.

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Earnings Look Back: Genesco Is Up 5.1% S...

When Genesco (NYSE:GCO) reported earnings two weeks ago on December 5th, 2014, analysts ...

Post Earnings Update: Vail Resorts Has C...

12 days ago, on December 8th, 2014, Vail Resorts (NYSE:MTN) reported its earnings. Ana ...

Cantel Medical Earnings Review: 10 Days ...

10 days ago, on December 10th, 2014, Cantel Medical (NYSE:CMN) reported its earnings. ...

ABM Industries Earnings Review: 12 Days ...

12 days ago, on December 8th, 2014, ABM Industries (NYSE:ABM) reported its earnings. A ...

Post Earnings Update: Gildan Activewear ...

Two weeks ago on December 4th, 2014 Gildan Activewear (NYSE:GIL) reported earnings and ...

Earnings Look Back: Christopher & Banks ...

When Christopher & Banks (NYSE:CBK) reported earnings two weeks ago on December 4th, 20 ...

Post Earnings Update: Methode Electronic...

9 days ago, on December 11th, 2014, Methode Electronics (NYSE:MEI) reported its earning ...

Phillips-Van Heusen Earnings In Retrospe...

Two weeks ago on December 3rd, 2014 Phillips-Van Heusen (NYSE:PVH) reported earnings an ...